Trametinib (Mekinist®)

Assessment Status Assessment process complete
HTA ID -
Drug Trametinib
Brand Mekinist®
Indication For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
Assessment Process
Rapid review commissioned 27/11/2015
Rapid review completed 22/12/2015
Rapid review outcome Full Pharmacoeconomic Assessment Recommended.
Full pharmacoeconomic assessment commissioned by HSE 27/07/2016
NCPE assessment completed 15/03/2017
NCPE assessment outcome Reimbursement Not Recommended at the submitted price.

Technical Summary

The HSE has approved reimbursement following confidential price negotiations; April 2018.